Real-World Clinical Effectiveness And Safety Of Olaparib Monotherapy In Her2-Negative Gbrca-Mutated Metastatic Breast Cancer: Phase Iiib Lucy Interim Analysis.
JOURNAL OF CLINICAL ONCOLOGY（2020）
Abstract
1087Background: OlympiAD (NCT02000622) demonstrated the benefit of olaparib over standard of care in patients (pts) with HER2-negative (HER2-) metastatic breast cancer (MBC) and germline BRCA mutat...
MoreTranslated text
Key words
olaparib monotherapy,metastatic breast cancer,breast cancer,real-world,gbrca-mutated
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined